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PART A:  ABSTRACT and STUDY PROTOCOL 
Abstract: 
Objective: This retrospective observational study aims to review patients with 
Malignant Ovarian Germ Cell Tumours (MOGCTs) treated at Groote Schuur 
Hospital over a 15 year period. The disease profiles, treatment modalities used, 
overall and disease free survival rates for each category were analysed. In addition, 
the HIV status and outcome for HIV positive patients were examined. 
Method: A medical chart review of adult patients with MOGCTs treated between 
1994-2008 was conducted. Data were collected in customized data sheets for transfer
to an electronic spread sheet. The Kaplan-Meyer method was used to obtain 5-year
survival data.
Results: Forty patients were treated for MOGCTs. Median age at the time of
diagnosis was 30.2 years (range 13-63 years). Ten patients (25%) had dysgerminoma
and 30 (75%) had non-dysgerminoma tumour types. The latter group comprised 
immature teratoma in ten yolk sac tumour in eight, and mixed germ cell tumour in
three patients, while nine patients had mature teratoma with malignant 
transformation. Nineteen patients were FIGO stages I-II and twenty-one were stages 
III –IV. Fertility sparing surgery was performed in most patients (77.5%). Twenty-
eight patients received chemotherapy, mostly with a three-day platinum based 
chemotherapy regimen (BEP).
Excluding the group with monodermal malignant transformation in mature teratoma
(MTMT), complete response to primary treatment was achieved in 24 of 31 patients 
(77.4%). After a median follow up of 42.5 months (range 2-60), overall five year
survival rate was 69.1%, and disease free survival rate was 90.6%. Of five HIV-
positive patients, three had died from MOGCT. Four of the nine patients with MMT
are alive after five years.
Conclusion: The prognosis for MOGCTs is excellent if managed with standard 
treatment initially. Treatment of MTMT is less well defined. Patients with advanced 
HIV infection did poorly and should be considered for initiation of antiretroviral 













This study aimed to look at the disease profiles and treatment outcomes for those 
patients with ovarian germ cell tumour who presented to Groote Schuur Hospital 
(GSH) during the 15-year period of 1994-2008. In order to perform this audit, a 
study proposal was prepared to guide our steps throughout this process. 
A letter was submitted to the Human Research Ethics Committee of the University of 
Cape Town’s Faculty of Health Science for approval. Permission to conduct the
study was also sought from the Clinical Directorate of Groote Schuur Hospital
(GSH). Permission to proceed was obtained from both (see Addendum).
Patients charts: 
To perform the audit, a list of all adult patients with MOGCTs registered at GSH 
between 1994 and 2008 will be obtained from the Gyn-Oncology Database of the 
Department of Radiation Oncology. For this study, “adult” is defined as 13 years or
older; this being the traditional cut-off age used at the associated tertiary hospitals of
the University of Cape Town, while the Surveillance, Epidemiology, and End 
Results (SEER) programme in America uses 15 years (Associate Prof. A. Davidson, 
personal communication, 12 January 2012). As cited by Butow et al., the definition 
used by the WHO for adolescents and young adults is an age group of 12-25 years.
1
All the patients to be included in this study were diagnosed with histologically 
confirmed primary germ cell tumour of the ovary, of any FIGO stage, during the 
chosen 15-year period of 1994-2008. There are no exclusion factors except for the 
extra-gonadal germ cell varieties. 
Data from the medical records of these patients will be extracted and recorded on 
customized data sheets (see Addendum), and then transferred to an Excel 
spreadsheet. As a quality assurance procedure, all extracted data are to be reviewed 
twice from the source documents (patient charts), then cross checked with data on 











The data points to be collected include age, date of registration (defined as date of 
first treatment = primary surgery in all cases), FIGO stage, histological types, 
classified broadly into Dysgerminoma (“Dysg”) and non-Dysgerminoma (“non-
Dysg”), collectively called malignant ovarian germ cell tumours (“MOGCTs”), and 
malignant somatic transformation in a mature teratoma, or monodermal teratoma 
(“MTMT”). The reason for studying the latter group separately is due to the different 
characteristics and clinical behaviour of the MTMT variety. 
For the primary treatment(s), the type of surgery, whether fertility preserving surgery 
or more radical surgery, is to be documented; also, the regimen and number of cycles 
of chemotherapy administered, and any major side effects experienced by the 
patients, and/or radiotherapy details are to be recorded.  
Laboratory values of HIV status (and CD4 count, if positive), and the initial levels of 
serum tumour markers will be noted (ß-HCG, LDH, AFP, and CA125, whenever
available).
Regarding the follow-up of patients, data will be recorded about response to primary
treatment, date of response, and current status (alive or dead, alive with disease or
disease-free, or lost) at last follow-up. In addition, the site(s), date and the treatment
of confirmed disease recurrence will be recorded. For this study, follow up of living 
patients is truncated at five years after their registration dates.
Treatment: 
Regarding the study population and setting, the period of review in the current 
study includes the time when the BEP chemotherapy regimen was already
established as standard treatment in MOGCTs;
2
consequently, with one notable
exception, all our patients received BEP as first line chemotherapy. The noticeable 
exception is the small group of patients with MTMT histology, where the intention
was to treat according to the histological subtype which had undergone malignant
transformation. These patients received a chemotherapy regimen purportedly specific 
to their particular subtypes.
All of the patients receiving BEP were subjected to a 3-day BEP regimen, 
administered as inpatients; the BEP regimen comprised cisplatinum 35mg/m2 I.V, 












three weeks). Generally, all patients are required to have an initial audiogram and 
adequate renal function prior to chemotherapy (a creatinine clearance > 50 
ml/minute, calculated using the Cockroft-Gault formula).   
Prehydration fluids with 1L N-Saline and two ampules MgSO4 over two hours were 
administered on day 1 before each chemotherapy cycle and anti-emetics with 
dexamethasone 8mg and 5HT3 antagonist I.V, day 1-2-3 were used. The cisplatinum 
was given in 200ml N-Saline over two hours simultaneously with 500 ml Mannitol 
for diuresis. This was followed by bleomycin 15 IU in 1L Plasmolyte B over six 
hours, then 1L N-Saline 6-8 hourly x 2 as post-hydration fluids. 
 At GSH, carboplatinum is used if there are contraindications to cisplatinum 
administration in an individual patient. Bleomycin was omitted if there is a 
contraindication, or after a cumulative dose of 300 IU, since exceeding this dose puts 
a patient at risk for developing pulmonary toxicity. 
Since no randomised studies exist for MOGCTs to determine the optimal number of 
cycles, empirical practice is to use three cycles of BEP for stage I, four cycles for 
completely resected stage II-IV and stage IV Dysg, and up to six cycles for stage II-
IV with residual disease. Where a marker is present, 1-2 cycles after normalization is 
advised.
3 
Such an approach has been the practice in our unit as well.  
Statistical analysis 
The patients’ demographics, disease and treatment characteristics will be 
summarized using descriptive statistics using Excel statistical tools and expressed as 
numbers, with a percentage value as well. Where appropriate, a mean or median 
value is given. 
 For tumour response, the original 1981 World Health Organization response 
definitions are used:
4      
 Complete response (CR): The disappearance of all known disease, 
determined by two observations not less than four weeks apart. 
 Partial response (PR): 50% or more decrease in total tumour load of the 
lesions that have been measured to determine the effect of therapy by two 











No response (NR): A 50% decrease in total tumour size cannot be established 
nor has a 25% increase in the size of one or more measurable lesions been 
demonstrated. 
Progressive disease (PD): 25% or more increase in the size of one or more 
measurable lesions or the appearance of new lesions. 
The actuarial overall survival rate (OS) at five years will be determined using the 
Kaplan-Meier method. The initial date is that of commencement of any therapy, 
whilst patients will be censored at the date of death, or last follow-up.   
The disease-free survival (DFS) is calculated from the date of first therapy to the date 
of confirmed recurrence in those patients who had achieved a complete response to
primary therapy, or to the date of last follow-up, or death, where recurrence had not 
occurred. The 5-year OS and DFS curves will be constructed using the Kaplan-Meier
method. Comparison between groups is made with the log rank method using PRISM
























PART B:  LITERATURE REVIEW   
Introduction 
The objective of this review is to provide the reader with the background and 
justification for the research, to describe what work has been done in this field by 
others, then collate this information and examine, evaluate and establish its 
relevance. Analysis of this information and comparison with results of other 
researchers may allow identification of what is new, different, or confirmatory. It 
may identify areas where further study is needed. 
The literature review is therefore an extensive search of the field of study and the 
theory behind it, with the aim of discovering related concepts and the potential 
relationship between them. Another important rationale for this review is simply to
identify potential sources of information for conducting the research.
For the current project, studies conducted between 1970 and the present, addressing
germ cell tumours, were searched for. The usual sources were used: PubMed, Google
Scholar, reference lists in text books and journal articles. The available English
language literature was scanned for any meta-analyses, randomised control trials and 
case series or even case reports. There are many studies of germ cell tumours in the
paediatric population. However, since the focus of this research is the adolescent and
adult, these paediatric studies will not be reviewed in detail and will only be referred 
to if necessary.
Studies of extra-gonadal germ cell tumours are excluded from this review, with the
focus being on primary ovarian germ cell tumours. However, the literature on
testicular germ cell tumours cannot be ignored since it includes much larger cohorts
of patients and there are similarities with treatment.  
In this review the focus will be on: 
a) Background and histological types.
b) Diagnosis and staging.
c) Tumour markers and prognostic factors.
d) HIV and germ cell tumours.












a) Background  and histological types:
Malignant ovarian germ cell tumours (MOGCTs) comprise a unique group of 
malignancies with widely varying subtypes and behaviours. Often they are highly 
malignant and rapidly growing tumours, but in general, they are more curable than 
their epithelial counterparts.
3,5
They are rare cancers accounting for less than 5% of all ovarian neoplasms, 
predominantly affecting young girls and adolescents in their reproductive age.
3
The
median age at diagnosis is 18 years and incidence is inversely proportional to
advancing age, according to Surveillance, Epidemiology, and End Results (SEER)
data of malignant germ cell tumors (1973-2002).
5,6
From the SEER database, the 30-year, age-adjusted incidence rate per 100,000 
women-years was 0.338; the 5-year survival rate was 83.9%. Survival rates improved
significantly between 1973 and 2002 and factors affecting survival included the
histological subtype, race, stage of disease, and age at diagnosis.
5
In a report from the 
National Cancer Institute in four member countries (Cyprus, Egypt, Israel, and
Jordan) of the Middle East Cancer Consortium (MECC) the incidence of germ cell
tumour between 1996-2001 was 2.2%, 3.3%, 7.2% and 10.8% in Cyprus, Israel,
Egypt and Jordan, respectively, compared to 3.0% in the US SEER data.
7
MOGCTs derive from primitive germ cells of the embryonic gonadal ridge; these
primordial cells migrate into the latter at six weeks of embryonic life. Subsequently
these tumours tend to have a spectrum of histological differentiation that normally
assembles the primitive developing embryo. Dysgerminoma (Dysg) arises from 
undifferentiated tissue, and endodermal sac or yolk sac (YST) tumours show 
malignant tendency in extra-embryonic differentiation. Whereas immature teratomas
(IT) derive from somatic differentiation from all three primitive germ cell lines,
6
recent studies propose that Dysg may be the antecedent of some of the other germ 
cell tumours.
8
Ovarian germ cell tumours are broadly classified as Dysgerminoma  (Dysg), which is 













 The most frequently encountered types of non-
dysgerminomatous tumours are immature teratomas (IT), mature teratoma with 
malignant transformation (MTMT), yolk sac tumour (YST), also known as 
endodermal sinus tumour, and mixed germ cell tumours. Less common types are 
embryonal carcinoma, nongestational choriocarcinoma and polyembryoma.
9 
This
wide subdivision is an important distinction, as it plays an important role in the 
treatment and prognosis for these patients.
10,11 
The recent WHO classification system for MOGCTs was conducted by Tavassoli 
and colleagues with comprehensive details regarding clinico-pathologic 
characteristics, as well as guidelines for the pathologist for precise diagnosis.
12
 Table
1 below shows a modified version of their classification.
13
According to the WHO system, the germ cell tumours are divided into three broad
categories: primitive germ cell tumours, biphasic or triphasic teratoma, and thirdly, 
monodermal teratoma and somatic-type tumours associated with biphasic or triphasic 
teratoma (“dermoids”). This division allows for a clearer distinction between
primitive germ cell tumours and the teratoma group. Moreover it allows for the
accurate placement of specific subtypes which have elements of both teratoma and 
somatic neoplasm such as struma ovarii.
12,13
Of 1262 cases identified by the SEER 
study of MOGCTs between 1973 and 2002, 32.8% had Dysg, 35.6% had IT, and
28.7% had Mixed GCTs.
5
b) The diagnosis, staging and tumour markers:
Because of the relative rarity of MOGCTs it was difficult to develop clinical profiles 
of patients with various histological types, though over time, clinical descriptions 
have improved. Pain and abdominopelvic mass are the commonest presentation in 
young women.
14
 Sometimes the diagnosis is only established at the time of surgery
when the presentation is one of acute abdomen. Abdominal distension and vaginal 
bleeding can also occur and the duration of symptoms are usually short (2-4 weeks). 
These tumours are usually unilateral, though they can occur bilaterally in up to 15% 
of cases with Dysg histology.
15
The evaluation of these patients should include routine blood tests, specifically 











important role in the diagnostic imaging of these tumours, revealing solid and/or 
cystic components.
12
Table 1: WHO classification of the Germ Cell Tumour 
(modified version, used with permission of publishers
13
)
I. Primitive germ cell tumours
A. Dysgerminoma




F. Mixed germ cell tumour (specify components)
1. Diffuse embryoma variant




2. Cystic (dermoid cyst)
3. Fetiform teratoma (homunculus)
III. Monodermal teratoma and somatic-type tumours associated
with biphasic or triphasic teratoma
A. Thyroid group
B. Carcinoid group




G. Sebaceous tumour group
H. Pituitary-type tumour group












Table 2. FIGO staging. 
Stage I Growth limited to the ovaries. 
 Ia Growth limited to one ovary: no ascites present containing malignant cells. 
No tumour on the external surface; capsule intact. 
 Ib Growth limited to both ovaries: no ascites present containing malignant cells. 
No tumour on the external surfaces; capsules intact. 
 Ic Tumour either Stage Ia or Ib, but with tumour on surface of one or both 
ovaries, or with capsule ruptured, or with ascites present containing 
malignant cells, or with positive peritoneal washings. 
Stage II Growth involving one or both ovaries with pelvic extension. 
 IIa Extension and/or metastases to the uterus and/or tubes.
 IIb Extension to other pelvic tissues. 
 IIc Tumour either Stage IIa or IIb, but with tumour on surface of one or both
ovaries, or with capsule(s) ruptured, or with ascites present containing
malignant cells, or with positive peritoneal washings.
Stage III Tumour involving one or both ovaries with histologically-confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or
inguinal nodes. Superficial liver metastases equal Stage III. Tumour is
limited to the true pelvis, but with histologically-proven malignant extension
to small bowel or omentum.
 IIIa Tumour grossly limited to the true pelvis, with negative nodes, but with
histologically-confirmed microscopic seeding of abdominal peritoneal 
surfaces, or histologically- proven extension to small bowel or mesentery.
 IIIb Tumour of one or both ovaries with histologically-confirmed implants,
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm
in diameter: nodes are negative.
 IIIc Peritoneal metastasis beyond the pelvis > 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
Stage IV Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allocate a case to Stage 
IV. Parenchymal liver metastasis equals Stage IV.
These tumours are staged according to the International Federation of Gynaecology 













On presentation, approximately 60-70% of cases of MOGCTs are FIGO stage I-II, 
whereas 10-20% are stage III, with stage IV being relatively rare. This is in contrast 
to epithelial ovarian cancer where later presentations are the norm. Spread is via the 
lymphatics, blood stream, or dissemination via the peritoneal surface.
3,15
c) Tumour markers and prognostic factors
Many MOGCTs produce the following tumour markers: Beta-human chorionic
gonadotrophin (ß-HCG), alpha feto-protein (AFP) and lactate dehydrogenese (LDH). 
These, when elevated, provide a highly sensitive and specific indicator of the
presence of certain histological components. Furthermore, serial assay for these
tumour markers is useful for monitoring the response to chemotherapy pre-
operatively, post-operatively and for subsequent follow up.
3,11,15
ß-HCG and AFP are specific markers for MOGCTs, the latter marker commonly
being raised in YST. ß-HCG can be elevated in 5% of Dysg and the combination of
both markers suggests the presence of mixed GCT. LDH is a non-specific tumour 
marker which can be found in 88% of the germ cell tumours; however it can be of
value in assessing response to therapy, or detecting a recurrence, particularly with
Dysg. Similarly, even CA-125 elevation can reflect a tumour progression.
3,9,15
Several prognostic factors have been reported for MOGCTs: an advanced stage, 
specific histological types (non-Dysg/immature histology) and bulky residual disease
after surgery were significantly associated with a worse overall survival.
15
In a study
conducted by Li et al., on patients with chemo-refractory disease, it was found that 
an advanced stage, non-Dysg\IT histology, and residual tumour after salvage
chemotherapy, were prognostic factors portending poor outcome.
17
Murugaesu and
co-workers reported that elevation of both AFP and ß-HCG was a strong predictor of
survival, compared to elevation of either marker alone.
18
In a recently reported large study of 613 patients, Kumar et al. found that the 
presence of lymph node metastasis is also a poor prognostic factor.
19 
Other
independent prognostic factors associated with relapse are non-platinum 
chemotherapy, very high AFP and pure YST histology.
20
d) HIV and germ cell tumours
Concerning the occurrence of germ cell tumours in patients with human 











reproductive age. The co-existence of HIV and MOGCTs is becoming more 
common, especially over the last decade as the HIV pandemic has become 
established in some parts of the world. Since the literature for testicular germ cell 
tumours is more voluminous than for their ovarian counterparts, it is not surprising 
that guidelines exist for the management of HIV-infected men with germ cell 
tumours.
21,22
A search of the literature concerning MOGCTs and HIV has revealed a single case
report for a South African patient,
23
a 16 year-old female, CD4 count of 903, with a
stage IA tumour. A unilateral-salpingo-oopherectomy was done and she was able to
complete four cycles of BEP chemotherapy and remain disease free and alive one
year after treatment.
23
Another two cases were identified in the literature with
immunosuppression and Dysg histology; since both were on immunosuppressive
drugs, the authors believed that there is an association between immunosuppression 
and MOGCTs.
24
Because the literature on MOGCTs and HIV infection is sparse, it seems reasonable 
to extrapolate management guidelines from the testicular cancer literature for women 
with germ cell tumours. 
e) The management and outcome of the disease
There have been no randomised trials of therapy for the MOGCTs due to their 
relative rarity; information on current management comes from retrospective reviews 
of patients’ treatment outcomes and from some multi-centric prospective trials. 
Treatment strategies have also been adopted from prospective trials, some 
randomised, conducted on their more common counterparts, the male germ cell 
tumours.
9,15 
It is not surprising, therefore, that a recent attempt by the esteemed
Cochrane group to conduct a meta-analysis of the benefits of chemotherapy in adult 
MOGCTs was unsuccessful.
25 
Surgery is the initial treatment of choice: to establish the diagnosis, stage, and to 
completely remove, or optimally debulk the tumour. Since this disease 
predominantly affects young females, conservative surgery to preserve fertility is the 
norm.
3 
In general, the treatment principles for all types of MOGCTs are similar to
those that guide the management of epithelial ovarian cancer (EOC), though with 











allows for the potential of fertility-sparing surgery, rather than total abdominal 
hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO). Fertility 
preservation without compromising the chance of cure is feasible, even in extensive 
and metastatic disease. The relatively lower frequency of advanced stage disease, the 
excellent sensitivity to platinum-based chemotherapy, and the lower incidence of 
severe late effects are other differences from the EOCs.
3,11,15
A second-look operation (SLO) is generally unnecessary in completely resected, or
tumour marker positive MOGCTs. In immature teratoma, however, whether pure or
mixed with other MOGCTs, post-chemotherapy radiological assessment and second-
look surgery operations are often employed. The reasons for a mainly surgical 
approach for all residual masses detected soon after chemotherapy, or even years
later, would be diagnostic; the aim would be to exclude malignancy, prevent a
“mature growing teratoma syndrome”, to relieve pressure symptoms from such a
mass, and to prevent subsequent dedifferentiation of teratoma into a cancer.
15,26
Concerning so-called “chemotherapeutic retro-conversion”, the underlying
mechanism could either be maturation of immature teratomatous elements under the
influence of chemotherapy, or destruction of immature teratoma in metastases
containing both mature and immature components. The latter seems the more likely,
though it is uncertain why these benign masses should sometimes be enlarging
(growing teratoma syndrome); perhaps this is the phenotypic outcome of the inherent
growth potential of the primitive foetal tissue?
26,27
The recommended post-operative treatment approach for MOGCTs is chemotherapy. 
Historically, the evolution of the chemotherapeutic treatment of MOGCTs was the
most important advance in the clinical management of these tumours. Before the
1970s and the advent of combination chemotherapy, the prognosis for patients with
MOGCTs was dismal. Virtually all patients with advanced-stage disease died, and
even in apparent stage I disease, only 5% to 20% of patients survived after surgery
alone. Over the past 30 years, the therapeutic approach has evolved along similar
lines to that used for testicular germ cell tumours. Initially, the combination of
vincristine, dactinomycin, and cyclophosphamide (VAC) became the standard. 
However, despite high response rates, cure rates in patients with advanced MOGCT 












The introduction of cisplatin-based chemotherapy (cisplatin, vinblastine, and 
bleomycin - PVB) proved to be effective and improved survival in male patients with 
refractory testicular cancer. Subsequently, the BEP (bleomycin, etoposide and 
cisplatin) combination showed equal efficacy with less toxicity in this 
population.
11,19,28 
Therefore, while both regimens have become incorporated into the
first-line treatment of patients with MOGCTs post-operatively, BEP is the current 
standard of care for these patients. The exceptions are stage I, grade 1 IT, and stage 
IA Dysg, in which adjuvant chemotherapy can be omitted.
28
In MOGCTs nowadays, cure rates approach 95–100% in early stage disease and 75–
80% in advanced disease. Dysg has a cure rate of over 95%, even in advanced 
disease.
11,19,28
It should be noted that in the standard BEP regimen, cisplatin and etoposide are
usually administered over 5 days, whereas bleomycin is administered weekly. The
Gynaecologic Oncology Group (GOG) used this regimen in a study involving 93
patients with MOGCTs. While the DFS rate was an excellent 89%, acute toxicity
was described as “moderate”. The reporting of treatment-related toxicities can be
criticised in this paper, since most patients were reported as having “some degree of 
myelosuppression”. Ten patients experienced febrile neutropaenia. Muco-cutaneous 
toxicity is mentioned in passing as being “fairly common”. Overall, there were no 
drug-related deaths. The incidence of neuro- or ototoxities is not mentioned, though 
pulmonary toxicity was not observed. Whether treatment delays occurred was also 
not described.
28
In testicular tumours, the EORTC/MRC have examined the BEP regimen in a large 
study of patients with the good prognosis subgroup. A 2 x 2 factorial design was 
used to compare three cycles of BEP versus 3 BEP + 1 EP, and BEP 5-day versus 
BEP 3-day administration.  The doses of the 3-day BEP regimen were cisplatinum 50 
mg/m2 I.V for days 1 and 2, etoposide 165mg/m2 I.V for days 1-3, and bleomycin 
15 mg weekly I.V x 3.
29
 The results have subsequently been updated, confirming
equivalence of three vs four cycles, as well as for the 5-day vs the 3-day regimen, 
although with more myelotoxicity with the latter. This did not, however, result in 
more dose attenuations. Non-haematological toxicity was similar. Where bleomycin 
is contra-indicated, four cycles of 5-day cisplatinum + etoposide (PE) is equivalent to 












Various modifications to the 3-day BEP regimen have been reported in treatment for 
MOGCTs with the aim of “increased convenience and less toxicity”.
31,32 
The issue of
equivalence of these modifications to the standard 5-day (or 3-day) BEP is of 
concern, and can only be established in randomised studies. There is, however, no 
strong evidence that these modified regimens are inferior.  
In a study from Greece, Dimopoulos et al. evaluated the safety and activity of a 3-
day modified (mBEP) regimen. These authors used BEP (cisplatin 40 mg/m2 IV for
days 1-3, etoposide 120 mg/m2 IV on days 1-3, and bleomycin 15 mg IV on days 1-
3). In a prospective study of 48 patients with MOGCTs (14 with dysg. and 34 with
Non-Dysg tumours), three cycles of mBEP for stages I–III, completely resected, or
four cycles for incomplete resection or stage IV, were administered on an outpatient 
basis. All patients with stages I/II and all with Dysg were cured, although 20 % of
patients with stages III/IV Non-Dysg experienced disease progression, especially if 
suboptimally debulked.
31
Interestingly, an even-shorter BEP regimen has been explored. Tay et al. used a 2-
day BEP in a pilot study of 31 patients with MOGCT’s.
33
While the overall DFS was 
93%, such modifications cannot be recommended without further study. It is also
tempting, for reasons of lower toxicity and ease of administration, to substitute
carboplatin for cisplatinum in the chemotherapeutic management of MOGCTs. In
testicular cancers, however, studies show that this approach yields inferior results.
34
Another important issue concerns the duration of treatment, in other words, the 
number of cycles to be given. With the 5-day BEP regimen, the GOG has
established, and recommended, that three cycles of BEP should be a standard
treatment for completely resected MOGCTs.
28
This study of MOGCTs notably
excluded all patients with dysgerminoma. Since radiotherapy has been replaced by
chemotherapy as post-operative treatment due to the fertility issues with the former,
it is therefore uncertain what the appropriate number of cycles of BEP is for Dysg.
There is no reason to believe, however, that Dysg would not require at least three
cycles of BEP, although the reduction of chemotherapy duration, or substitution of
cisplatinum by the less toxic carboplatinum requires further study.
3
Risk stratification in testicular germ cell tumours generally determines the number of 











randomised studies, exist for MOGCTs, empirical practice is to use three cycles of 
BEP for stage I, four cycles for completely resected stages II-IV and stage IV Dysg, 
and up to six cycles for stages II-IV with residual disease. Where a marker is present, 
one or two cycles should be given after normalization. Bleomycin should be omitted 
after a cumulative dose of 300 IU because exceeding this dose puts patients at risk of 
developing pulmonary toxicity.
3
In the past, the use of radiotherapy was reserved Dysg histology. For instance, for 
patients with stage III disease, retroperitoneal and para-aortic lymph nodes were 
treated with pelvic or whole abdomen radiotherapy. This practice went out of favour 
due to the high sensitivity of these tumours to chemotherapy, as well as the long term 
toxicity of the radiation and fertility issues.
9
Concerning the outcomes of MOGCTs, the Hellenic Cooperative Oncology Group
reported on a series of 13 patients with Dysg and 40 patients with Non-Dysg. The OS 
at five years was 87% for the entire group, being 100% for patients with Dysg and 
85% for patients with Non-Dysg tumours. Even in patients with advanced Non-Dysg
tumours and residual disease after surgery, 85% remained disease free.
35
Lai et al. reviewed a larger cohort of 93 patients. The 5-year survival rate was 97% 
for those treated primarily at their hospital; the OS for Dysg versus Non-Dysg was
100% and 83.3%, respectively.
36
In another series of 113 patients with MOGCTs 
(stages IC to IV), it was demonstrated that long-term outcome of patients with
MOGCTs is excellent, with 5, 10, and 25-year estimated survival rates of 83%, 81%,
and 81%, respectively.
19
Due to the relative rarity of these tumours, a degree of heterogeneity in these 
retrospective studies is inevitable and randomised studies are difficult to perform. 
Nevertheless, these case series indisputably are of value in assessing treatment 
outcomes, since these provide the only evidence-based information from which 
management guidelines for this population could be derived, apart from indirect 
evidence from the testicular germ cell tumour experience. 
f) Conclusion
It is established that fertility preserving surgery and the BEP post-operative 











patients is excellent, even in advanced disease. This latter group, however, may 
require further management standardization. The association between HIV and 
MOGCTs also requires further study. 
This literature survey has been informative for this student insofar as it, to quote 
Marshall and Rossman (1999), built “a logical framework for research and set it 
within a tradition of enquiry and a context of related studies”.
37 
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Abstract 
Objective: This retrospective observational study aims to review patients with 
malignant ovarian germ cell tumours (MOGCTs) treated at Groote Schuur Hospital 
over a 15-year period.  
Method: A medical chart review of adult patients with MOGCTs treated between 
1994 and 2008 was conducted. Data gathered were transferred to an electronic
spreadsheet. The Kaplan-Meyer method was used to obtain 5-year survival data.
Results: Forty patients were treated for MOGCTs. Median age at the time of
diagnosis was 30.2 years (range 13-63 years). Ten patients (25%) had dysgerminoma
and 30 (75%) had non-dysgerminomatous types. The latter group comprised
immature teratoma in ten, yolk sac tumour in eight, and mixed germ cell tumour in 
three patients, while nine patients had mature teratoma with malignant 
transformation. Surgery was with fertility-sparing procedures wherever possible.
Chemotherapy entailed a 3-day modified BEP regimen during the period of the
study.
Excluding the group of nine with monodermal malignant transformation in mature 
teratoma (MTMT), complete response to primary treatment was achieved in 24 of 31 
patients (77.4%). After a median follow up of 42.5 months (range 2-60), overall 5-











survival rate was only 40%. Four of the nine patients with MTMT are alive after five 
years. 
Conclusion: The prognosis of MOGCTs is excellent if managed with standard 
treatment initially. Treatment of MTMT is less well defined. Patients with advanced 
HIV infection did poorly and should be considered for initiation of antiretroviral 
therapy prior to chemotherapy.  
Keywords: 
Malignant Ovarian Germ Cell tumours, fertility-sparing surgery, chemotherapy, HIV 
infection. 
Corresponding author: Khadiga Mohammed [khadijaelfadil22@hotmail.com] 
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Introduction 
Malignant ovarian germ cell tumours (MOGCTs) comprise a unique group of
malignancies which derive from primitive germ cells of the embryonic gonadal 
ridge. They account for less than 5% of all ovarian neoplasms and have widely
varying subtypes and behaviours. Although highly malignant and rapidly growing
tumours, they are generally more curable than their epithelial counterparts.
1,2,3
It is
imperative that these tumours be managed from the outset with accurate diagnosis, 
staging and treatment.
They are broadly classified as dysgerminomas (Dysg), the most common type and 
the counterpart of the male seminoma, and a non-dysgerminomatous group (non-
Dysg).
2,4 
This classification plays a role when it comes to the treatment and prognosis
for these patients.
5,6  
A modified sub-classification of the ovarian germ cell tumours
is shown in Table 1.
7
There have been no randomised trials of therapy for MOGCTs due to their relative 
rarity. The data on which management is based derive from retrospective reviews of 












Treatment strategies have also been adopted from prospective trials, many of them 
randomised, conducted in their more common counterparts, the male germ cell 
tumours.
4,8
 It is not surprising, therefore, that a recent attempt at a meta-analysis of 
the benefits of chemotherapy in adult MOGCTs by the Cochrane group was 
unsuccessful.
9 




I. Primitive germ cell tumours 
A. Dysgerminoma 
B. Yolk sac tumour 
C. Embryonal carcinoma 
D. Polyembryoma 
E. Nongestational choriocarcinoma 
F. Mixed germ cell tumour (specify components) 
1. Diffuse embryoma variant 
 
II. Biphasic or triphasic teratoma 
A. Immature teratoma 
B. Mature teratoma 
1. Solid 
2. Cystic (dermoid cyst) 
3. Fetiformteratoma (homunculus) 
 
III. Monodermal teratoma and somatic-type tumours associated 
with biphasic or triphasic teratoma 
A. Thyroid group 
B. Carcinoid group 
C. Central nervous system tumour group 
D. Carcinoma group 
E. Melanocytic group 
F. Sarcoma group 
G. Sebaceous tumour group 
H. Pituitary-type tumour group 





(modified by Roth et al 
7
 – used with permission from publisher) 
 
A survey of patients with MOGCTs treated at Groote Schuur Hospital (GSH) over a 
15-year period is presented. The histological types, treatment applied, and outcomes 













Materials and methods  
Approval from both the Research Ethics Committee of the Faculty of Health Science, 
University of Cape Town, and the Clinical Directorate of Groote Schuur Hospital 
was obtained to conduct this retrospective observational study. Patients were not 
identified and therefore their consent was not required. 
To perform the audit, a list of all adult patients with primary MOGCTs registered at 
GSH between 1994 and 2008 was obtained from the Gyn-Oncology database of the
Department of Radiation Oncology. “Adult” was defined as 13 years or older, this 
being the traditional cut-off age used at the associated tertiary hospitals of the 
University of Cape Town. Data from the medical charts of these patients were
extracted and recorded on customized data sheets, then transferred to an Excel
spreadsheet. As a quality assurance procedure, all extracted data were reviewed twice
from the source documents (patient charts), then cross checked with data on the Gyn-
Oncology database.
The data points collected included age, date of registration (defined as date of first 
treatment = primary surgery in all cases), histological type, and FIGO stage. For the
primary treatment(s), the type of surgery, the regimen and number of cycles of
chemotherapy administered, and/or radiotherapy details were recorded. Laboratory
values of HIV status (and CD4 count, if positive) and the initial levels of serum
tumour markers were noted.
Regarding the follow-up of patients, data on response to primary treatment, date of
response, and current status at last follow-up were recorded, as well as the data on
site(s), date and treatment of confirmed disease recurrence. For this study, follow up 
of living patients was truncated five years after their registration dates. Patients’ 
demographic, disease and treatment characteristics were summarized using
descriptive statistics. The overall survival (OS) at five years was calculated from the
date of registration to the date of death, or last follow-up. The 5-year OS curves were
constructed using the Kaplan-Meier method. Comparison between groups was made
with the log rank test. Data were analysed using PRISM
R
statistical software version 5












Forty patients were found on the database for the defined study period. The median 
age at the time of diagnosis was 30.2 years (range 13-63 years).  Of the study 
patients, 31 had the usual types of MOGCTs, while nine had the unusual variants 
(see flow charts in Figure 1). 
Figure 1.  A) Flow chart of all the patients with MOGCTs, and B) with MTMT*. 
A)  
No adjuvant
chemo. n = 4
BEP 
n = 6 
 BEP 
n = 18 
No adjuvant 


















































n = 4 
Dysg 
n = 10 
Non-Dysg
n = 21 
USO 
+/ - O 
n = 9 
Biopsy
only 
n = 1 
Biopsy 
only 



























 n = 3
Stage I-II 
 n = 6
Adjuvant Rx
n = 4 
No chemo 
 n = 5 
USO +/- O 





NR 1 PD 1 CR 7 
DD  
n = 4 
Outcome 
Lost 
 n = 1 
NED 
 n = 4 
Planned Rx completed? 











Caption for Figure 1 and Table 2: Dysg.= dysgerminoma; IT= immature teratoma; YST = yolk sac 
tumour;  Mixed GCT=  mixed  germ cell tumour; MTMT = mature teratoma with malignant 
transformation; USO +/- O =unilateral salpingo-oophorectomy +/- omentectomy;  2
nd
 look = second 
look laparotomy; TAH+SO +/- O = total abdominal hysterectomy + salpingo-oophorectomy +/- 
omentectomy; BEP = bleomycin, etoposide and cisplatin; CR = complete response; NE = not 
evaluated; PR = partial response; PD = progression of the disease; NR = no response; LDH = lactate 
dehydrogenase; hCG = human chorionic gonadotrophin; AFP = alpha feta-protein; CA 125=cancer 
antigen; NED = no evidence of disease; DD = dead from disease; Planned Rx = Initial Rx 
recommended by multidisciplinary team – surgery with or without chemotherapy. 
Table 2. Characteristics of MOGCTs according to different histology types. 
Histology Dysg. IT YST Mixed GCT MTMT 
Age (median) 20.5 
 (range 14-63) 
23.2 
 (range 14-37) 
20.5 
 (range 1532) 
33
 (range 22-37) 
49 
(range 22-62) 
FIGO stage I  (40%) 



























2nd look 33.3% 
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44.5% 
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80% 100% 62.5% 66.6% 88.8% 
Response to Treatment CR 80% 
NE 20% 









Tumour marker elevated LDH  80% 
hCG  50% 
AFP 50% 
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These variants, abbreviated as MTMT, were either a malignant somatic 
transformation in a mature teratoma, or monodermalteratoma. Due to the different 
characteristics and clinical behaviour of the MTMT group, they were analysed 
separately from the 31 patients with the usual varieties of MOGCTs. 
The 31 patients with MOGCTs were broadly subdivided into Dysg. in 10 patients 
(32%) and a non-Dysg. group in 21 (68%). This latter group was made up from ten 
patients (32%) with immature teratoma (IT), eight patients (26%) with yolk sac 
tumour (YST, also known as endodermal sinus tumour), and three with mixed germ 
cell tumour (10%) (Table 2). 
A subsequent laparotomy was performed after a variable time in five patients with 
IT. A “growing teratoma” situation was found in two of these patients, and both 
remain well following the surgical resection of these masses.  
Overall, stage III (46%) was the most frequent presentation in the 31 patients with
the usual types of MOGCTs, followed by stage I (32 %), stage IV (19 %), and stage
II in only one patient (3%) – see Table 2. Fertility-sparing surgery was performed in
most patients (93.5%).  
Chemotherapy was administered to 24 of the 31 patients for a median of four cycles 
(range 1-7). All these patients received a 3-day BEP regimen (cisplatin 35mg/m2 I.V, 
etoposide 120 mg/m2 I.V, and bleomycin 15mg I.V, daily for three days, every three
weeks). Complete response to primary treatment (surgery with or without
chemotherapy) was achieved in 24 (77.4%) patients, a partial response in one (3.2%), 
and unresponsive or progressive disease in six (19.4%). Only two of the completely
responding patients experienced disease relapse, both with IT histology. After a
median follow up of 42.5 months (range 2-60 months), 71% patients were alive with 
no evidence of disease and 29% patients had died.
None of the 24 patients who had received chemotherapy showed any clinical features 
of bleomycin-induced lung toxicity. The only serious non-surgical morbidity 
recorded was of unexpected, severe hearing loss in one patient during her first cycle 
of BEP. Another died from neutropenic sepsis during salvage chemotherapy.  
The 5-year overall survival (OS) rate for the 31 patients with the usual types of 











compared to 65% for the non-Dysg. group. The 5-year OS for patients with stage I-II 
was 88.8% versus 58.3% for those with stage III-IV (p=0.069).  
Because of the older age of the MTMT group (median age 49 years versus 22 years 
for the other MOGCTs), hysterectomy, oophorectomy and omentectomy were 
performed more commonly (five of nine patients). The histology of the transformed 
line was squamous cell carcinoma in six patients and one each had leiomyosarcoma, 
insular carcinoid and struma ovarii, respectively. The latter three patients underwent 
surgery alone. For the group of six patients with squamous histology, adjuvant 
chemotherapy of various types was given to four, and pelvic radiotherapy to the 
pelvis to one patient. Only two of these six patients remain alive and disease free. For 
the nine patients with MTMT, the 5-year OS rate was 50%.  
Of the total cohort of 40 patients, the HIV status was known in only 19, of whom 
five were positive (Table 3). Only two patients with positive status completed 
planned treatment and remain in remission. Both had CD4 counts over 300, while the
three patients who died from progressive disease had CD4 counts <300, with poor
physical condition and poor compliance. The 5-year overall survival was only 40%
in the infected group compared to 61,5% in the negative patients and 74.7% in the
untested group.
Discussion 
MOGCTs are rare tumours, most of which occur at a critical point in the
development of young women. Most patients can be treated successfully with 
fertility-preserving surgery with or without chemotherapy.
2,5
Whilst the principles of
surgical staging for ovarian neoplasms were applied in the patients reported here, 
there was generally less inclination to perform extensive cytoreduction due to the
chemosensitivity of MOGCTs. In our study, the median age was 30.2 years, which
correlates with the natural history of this disease.
2,4,8
Most of our patients presented with non-Dysg. histology, a quarter had Dysg., while 
22.5% had a unique group of tumours, either malignant transformation within a 
mature teratoma, or monodermalteratoma, which is not dissimilar to the proportions 












Table 3. Characteristics of the five HIV-positive patients. 
Age (years) Histology 
type 











32 Dysg. IIIC 140 (USO + O) + 1 
cycle of PEB 
NE 37 DD 
22 YST IV 11 Bx +1 cycle of 
PEB 
PD 4 DD 
26 YST IIIC 214 (USO +O) +1 
cycle of PEB 
NE 5 DD 
22 YST IV 599 (USO + O) + 5 
cycles of PEB 
CR 60 NED 
46 MTMT IIC 337 (TAH + BSO +
O) + RT to the
pelvis
CR 60 NED 
The treatment of MOGCTs has been an area of great success in the field of
gynaecological oncology, largely attributable to the introduction of platinum based 
chemotherapy since the mid 1970’s.
11
The period of review in the current study
includes the time when the BEP chemotherapy regimen was already established as
standard treatment in MOGCTs,
11,12
hence all our patients received BEP as first-line
chemotherapy, albeit as modified 3-day cycles. The noticeable exception was for the 
small group of patients with MTMT histology where the intention was to treat
according to the histological somatic subtype which had undergone malignant 
transformation.
It should be noted that in the standard BEP regimen, cisplatin and etoposide are 
usually administered over five days, whereas bleomycin is administered weekly. The 
Gynaecologic Oncology Group (GOG) used this regimen in a study of 93 patients 
with MOGCTs. While the DFS rate was an excellent 89%, the reporting of 
treatment-related toxicities can be criticised in this report as it is not well 
documented. Whether treatment delays occurred was also not described.
13
In testicular tumours, the EORTC/MRC have examined the BEP regimen in a large 













subsequently been updated, confirming equivalence of three vs four cycles of BEP, 
as well as for the five day vs the three day regimen, although with more 
myelotoxicity with the latter. This did not, however, result in more dose attenuations. 
Non-haematological toxicity was similar. Where bleomycin is contra-indicated, four 
cycles of 5-day cisplatinum + etoposide (PE) is equivalent to three cycles of BEP.
15
Various modifications to the 5-day BEP regimen have been reported in treating 
MOGCTs with the aim of “increased convenience and less toxicity”.
16,17
The 3-day
modified BEP regimen has been used at GSH for these reasons in both male and
female germ cell tumours. The issue of equivalence of these modifications to the 
standard 5-day BEP is of concern, and can only be established in randomised studies. 
There is, however, no strong evidence that these regimens are inferior. In a study
from Greece, Dimopoulos et al. have evaluated the safety and activity of a 3-day
modified (mBEP) regimen which is similar to what has been used at GSH. In a
prospective study of 48 patients with MOGCTs (14 with Dysg. and 34 with non-
Dysg. tumours), all patients with stages I/II and those with Dysg. were cured, 
although 20 % of the patients with stages III/IV non-Dysg. experienced disease
progression, especially if suboptimally debulked.
16
Interestingly, an even- shorter BEP regimen has been explored. Tay et al. used a 2-
day BEP.
18 
While the overall DFS was 93%, such modifications cannot be
recommended without further study. It is also tempting to substitute carboplatin for
cisplatinum in the chemotherapeutic management of MOGCTs. In testicular cancers, 
however, studies show that this approach yields inferior results.
19
At GSH,
carboplatinum is only used if there are definite contraindications to cisplatinum
administration in an individual patient.
While Dysg. tumours are exquisitely radiosensitive, this modality is rarely used 
nowadays due to fertility concerns. None of the patients in the current study received 
radiotherapy as part of their planned primary treatments. 
In the current series, the 5-year OS rate was 69.1% for the group with “pure” 
MOGCTs (78.7% for Dysg. and 65% for the non-Dysg. group). Comparatively, in a 
report on 53 patients by the Hellenic Cooperative Oncology Group, the OS at five 
years was 100% for patients with Dysg. and 85% for patients with non-Dysg. 











after surgery, 85% remained disease free.
20
 Lai et al. reviewed a larger cohort of 93
patients. The 5-year survival rate was 97% for those treated primarily at their 
hospital; the OS for dysg. versus Non-dysg. was 100% and 83.3%, respectively.
21
 Another large analysis of 113 patients with MOGCTs with stages IC to IV 
demonstrates that the long-term outcome of patients with MOGCTs is excellent, with 
5, 10, and 25-year estimated survival rates of 83%, 81%, and 81% respectively.
22
Due to the relative rarity of these tumours, a degree of heterogeneity in these
retrospective studies is inevitable. The current study population, however, appears to
show somewhat inferior survival rates as compared to most reports. One important 
explanation for this finding is that six out of 31 patients (19.3%) did not complete
their primary treatment due to poor compliance with the treatment programme. In
addition, HIV seropositivity in three patients contributed to their inability to
complete treatment, as they were too ill. Both these factors constitute an impediment
to the treatment effectiveness of MOGCTs at GSH. Furthermore, the case mix in this
study shows that there were relatively more patients with advanced stages than in
other series, in which 60 to 70% of patients have stage I.
2,14,20
The current study
shows that 65% of the 31 patients had stage III-IV, with an OS of 58.3%, compared 
to 88.8% for those with early stage disease. The reason for the later stage
presentations to be more common amongst our patients is the restriction of access to
medical care.
There is no compelling reason to ascribe our inferior results to the 3-day BEP
regimen. The relatively small numbers involved in each subgroup, however, makes
detailed analysis difficult, and the limitations inherent in a retrospective study of this 
nature are recognized. A further limitation of the current study is that the potential
consequences of chemotherapy cycle delays were not studied. 
Concerning the occurrence of germ cell tumours in patients with human 
immunodeficiency virus (HIV) infection, the literature for testicular germ cell 
tumours is more voluminous than for its ovarian counterparts. Germ cell tumours are 
the most common solid neoplasm in men between the ages of 15 and 34 years and so 
it is not surprising that guidelines exist for the management of HIV-infected men 
with germ cell tumours.
23,24
 A search of the literature concerning MOGCTs and HIV
has revealed a single case report in a South African patient,
25











extrapolate management guidelines of the testicular cancer literature for women with 
germ cell tumours.  
The poor outcome of the HIV-positive patients (OS of only 40%) was chiefly due to 
the three patients who presented with poor physical condition and a low CD4 count 
(11- 214 cells\mL). They were simply too ill to be treated effectively and all three
died soon after their diagnosis. None received antiretroviral therapy (ART). The
other two patients whose CD4 counts were higher (599 and 337 cells\mL
respectively) were also not on ART but tolerated their adjuvant treatment well, and 
remain in remission. This limited experience suggests that immune status plays an
important role regarding the tolerance of treatment. Close surveillance of neutrophil
and CD4 cells counts, as well as the use of G-CSF and systematic anti-Pneumocystis 
carinii prophylaxis (PCP) are recommended during chemotherapy.
23
Clearly, the
timely introduction of ART may be beneficial for some of these patients.  
The subgroup of patients with MTMT in the current series had a survival rate of only
50%. Generally, these are rare tumours and occur typically in postmenopausal 
women.
26,27
Most malignant transformations are squamous cell carcinomas arising 
from the ectoderm; the rest are carcinoid tumours or adenocarcinomas.
26
A review of 37 patients with squamous carcinoma showed that the 5-year survival 
rates for adequately staged patients were 94.7% for stage I, 80% for stage II, and 0%
for patients with stage III and IV disease (p=.0001), all of whom died within 20 
months.
28 
A larger review of 227 cases assimilated from the literature showed that 
the overall 5-year survival rate for all stages was 48.4%. For Stage I, it was 75.7%,
for stage II 33.8%, 20.6% for stage III, and 0% in stage IV. Patients who received 
adjuvant cisplatinum (plus alkylating agent) appeared to do better. The MTMT are,
however, too rare and varied either for prospective studies to be performed, or for
good treatment guidelines to be forthcoming from the existing literature.
29
A final comment is worthwhile about the interesting phenomenon of “growing 
teratoma syndrome,” of which two cases were encountered in the current study.
30, 31
Both of these patients are in remission following surgical resection of these expansile 
masses. It is probably a phenomenon similar to another description found in the 












In conclusion, patients with MOGCTs treated at GSH between1994-2008 had a 
survival outcome perhaps slightly inferior to many reported series. The occurrence of 
poor compliance and HIV-related poor physical state, however, contributed to the 
poor outcome in some patients. Late state presentations were also more frequent in 
the current series. Fertility-sparing surgery and post-operative BEP chemotherapy 
were the standard treatments applied; the modified 3-day regimen was not obviously 
inferior in this small study.  
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Figure 2. 5-year Overall Survival. A: all the patients with MOGCTs (excluding MTMT 












1. Smith  HO, Berwick  M, Verschraegen CF, Wiggins C, Lansing  L, Muller CY, et al.
Incidence and survival rates for female malignant germ cell tumors. Obstet
Gynecol. 2006;107:1075-85.
2. Parkinson CA, Hatcher HM, Earl HM, Ajithkumar TV. Multidisciplinary
management of malignant ovarian germ cell tumours. Gynecol Oncol.
2011;121:625-36.
3. Tewari K, Cappucini  F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant
germ cell tumors of the ovary. Obstet Gynecol. 2000;95(1):128-33.
4. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol.
2007;25:2938-43.
5. Weinberg LE, Lurain JR, Singh DK, Schink JC. Survival and reproductive outcomes
in women treated for malignant ovarian germ cell tumors. Gynecol Oncol.
2011;121:285-9.
6. Bailey J, Church D. Management of germ cell tumours of the ovary. Rev Gynaec
Prac. 2005;5:201-6
7. Roth LM, Talerman A. Recent advances in the pathology and classification of
ovarian germ cell tumors. Int J Gynecol Pathol. 2006;25:305-20.
8. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer
Treat Rev. 2008;34:427-41.
9. Abdul Razak AR, Li L, Br ant A, Diaz-Padilla I. Chemotherapy for malignant germ
cell ovarian cancer in adult patients with early stage, advanced and recurrent
disease. Cochrane Database Syst Rev. 2011(3):CD007584.
10.Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al.
Incidence and survival rates for female malignant germ cell tumors. Obstet
Gynecol. 2006;107:1075-85.
11. Gershenson D, Morris M, Cangir A, Kavanagh J, Stringer C, Edwards C, et al.
Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide,
and cisplatin. J Clin Oncol. 1990;8:715-20.
12. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer.
1993;71(S4):1581-90.
13. Williams S, Blessing J, Liao S, Ball H, Hanjani P. Adjuvant therapy of ovarian germ
cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic
Oncology Group. J Clin Oncol. 1994;12:701-6.
14. de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Fosså SD, et al.











chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A 
randomized study of the European Organization for Research and Treatment of 
Cancer - Genitourinary Tract Cancer Cooperative Group - and the Medical 
Research Council. J Clin Oncol. 2001 March 15, 2001;19:1629-40. 
15. de Wit R,  Roberts J, Wilkinson P,  de Mulder P, Mead G, et al. Final analysis
demonstrating the equivalence of 3 BEP vs. 4 cycles and the 5 day schedule vs. 3
days per cycle in good prognosis germ cell cancer. An EORTC/MRC Phase III
Study. ASCO Annual Meeting 2000 (abstr 1281). Proc Am Soc Clin Oncol. 19:
2000.
16.Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis 
A, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide,
and cisplatin regimen: A prospective multicenter study. Gynecol Oncol.
2004;95:695-700. 
17.Linasmita V, Srisupundit S, Wilailak S, Tangtrakul S, Israngura N, Bullangpoti S. 
Recent management of malignant ovarian germ cell tumors: A study of 34 cases. J 
Obstet Gynaecol Res. 1999;25:315-20.
18.Tay S-K, Tan L-K. Experience of a 2-day BEP regimen in postsurgical adjuvant
chemotherapy of ovarian germ cell tumors. Int J Gynecol Cancer. 2000;10:13-8.
19.Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: A
Cochrane evidence-based systematic review. Cancer Treat Rev. 2002;28:237-53.
20.Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, 
Aravantinos G, et al. Favorable outcome of ovarian germ cell malignancies treated
with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative
Oncology Group study. Gynecol Oncol. 1998;70:70-4.
21.Lai C-H, Chang T-C, Hsueh S, Wu T-I, Chao A, Chou H-H, et al. Outcome and
prognostic factors in ovarian germ cell malignancies. Obstet Gynecol Surv.
2005;60:364-5.
22. Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al.
Malignant ovarian germ cell tumors: Identification of novel prognostic markers and
long-term outcome after multimodality treatment. J Clin Oncol. 2006 October 20,
2006;24:4862-6.
23. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, et al. Germ cell
tumors in patients infected by the human immunodeficiency virus. Cancer.
2001;92:1460-7.
24. Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC.












25. Moodley M, Moodley J. Ovarian germ cell malignancy and human
immunodeficiency virus (HIV) infection: A case report. Int J Gynecol
Cancer. 2003;13:541-2.
26. Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg H-R, Münstedt
K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: Systematic
review and analysis of published data. Lancet Oncol. 2008;9:1173-80. 
27. Tseng C-J, Chou H-H, Huang K-G, Chang T-C, Liang C-C, Lai C-H, et al.
Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol
Oncol. 1996;63:364-70.
28.Kikkawa F, Nawa A, Tamakoshi K, Ishikawa H, Kuzuya K, Suganuma N, et al.
Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the
ovary. Cancer. 1998;82:2249-55.
29.Chen R-J, Chen K-Y, Chang T-C, Sheu B-C, Chow S-N, Huang S-C. Prognosis and 
treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary.
Taiwan Yi Xue Hui Za Zhi. 2008;107:857-68.
30. Amsalem H, Nadjari M, Prus D, Hiller N, Benshushan A. Growing teratoma
syndrome vs. chemotherapeutic retroconversion: Case report and review of the
literature. Gynecol Oncol. 2004;92:357-60.
31. Hsieh T-Y, Cheng Y-M, Chang F-M, Chou C-Y. Growing teratoma syndrome: An
























Author  submission for SAJGO (South African Journal of Gynaecological Oncology): 
How to submit your paper online: 
1.Registered authors must login to submit a paper
2.Visit www.sajgo.co.za
3.Register on the website as an author and log in.
4.Click on LOG IN and log in with username and password if already registered
5.If you have forgotten your password click on �Forgot your password?�
6.If you are not registered, click on�Not a user? Register with this site.�
7.Select Author.
◦Click on CLICK HERE TO FOLLOW THE FIVE STEPS TO SUBMIT YOUR MANUSCRIPT.
◦Follow the five steps to submit your paper.
Please submit a cover letter as a supplementary file with the following:
1.Surnames, initials and qualifications of all authors in the correct sequence
2.Full contact details of corresponding author: Title, first name, surname, e-mail address, mobile,
office and fax number and postal address.
3.Declaration on copyright and originality of paper and acknowledgement of any third party sources




Review policy and timelines 
1.Immediate notification if submitted successfully











3.Notification within 3 months if accepted for publication, if revisions are required or if rejected by
both reviewers. 
4.Publication within 6 months after submission.
Article section and length: 
The following contributions are accepted (word counts exclude abstracts, tables and references): 
•Original articles describe original investigations at an acceptable degree of completion, constituting
an advance in the field. The body of the article must not exceed 3500 words of text. The abstract must 
either be structured and comprising no more than 250 words, or unstructured with a 200 word limit. 
Articles are limited to a maximum of 7 insets (tables and figures combined) and 50 references.  
•Review articles that are of high quality and of relevance to the field will be published. Manuscripts of
Reviews will be peer reviewed and should not exceed 2500 words and 25 references. Reviews will 
often be invited and unsolicited reviews are also considered.
•Brief Reports and Case Reports present complete studies that are narrower in scope than those
described in Original articles. These Reports include a highly focused abstract and are limited to a 
total of no more than 1500 words of text, a total of 4 inserts (tables or figures), and 15 references. 
Preferably include "Brief Report" or�Case Report� in the title.
•Pathologist�s, Radiologist�s and Surgeon�s Corners intend to describe a specific issue, finding or
technique that is new, of special interest or modified. This section is limited to 1000 words and up to 5
references and will be peer reviewed.
•Correspondence (Letters to the Editor) should be short and concise, commenting on a recently
published article in the Journal or a controversial or topical issue of concern to the readership. Please
prepare the letter in manuscript format, including a title page. The letter must not exceed 500 words, 3
authors, 1 insert (table or figure) and 5 references. A statement of potential sources of conflict of
interest must accompany the letter.
•Editorials and Commentaries are generally invited by the Editor and are overviews of articles of other
research or of issues of special interest to the subspeciality. Unsolicited commentaries are also 
considered. 
Document requirements 
Please include the following documents with your submission: 
Cover letter stating that the manuscript has not been submitted or accepted for publication elsewhere and that 
it is the original work contributed to and approved by all the author(s). 












 Manuscript which should contain a title page, abstract, text and references. It may also contain tables and 
figures, acknowledgements and a foot note page. 
Manuscript requirements 
Title page 
On the title page, please supply a running head of not more than 40 characters and spaces, a title of not more than 160 
characters and spaces, the names and affiliations of all the authors in the correct sequence and word counts of the 
abstract and text. Each author�s first name, subsequent initials and surname must be used. Also supply the contact 
details of corresponding author.  
Authorship 
Authorship should be based only on a substantial contribution to conception, analysis and interpretation of data; writing 
the article or revising it critically and final written approval of the version to be published. The Journal uses the Uniform 
Requirements of Authorship for Manuscripts Submitted to Biomedical Journals as published online at 
www.icmje.org/index.html and all three of these conditions must be met. 
Abstract 
The abstract may be structured with the headings Background, Methods, Results, and Conclusions (250-word limit) or 
unstructured (200-word limit). Abstracts of Brief Reports should be no more than 100 words. The abstract must state the 
purpose of the research, the methods, results and conclusions. Include up to 10 key words, separate from the abstract. 
Text 
Please refer to the manuscript categories for the prescribed length of the text. The Editor reserves the right to shorten 
and stylise any material accepted for publication. Authors are solely responsible for the factual accuracy of their work. 
The manuscript must be in English, should be in MS Word and follow the Vancouver style. Abbreviations and 
acronyms should be defined on first use. Pages should be numbered consecutively preferably with sections for 
introduction, materials and methods, results, discussion, acknowledgements followed by references. 
Ethical considerations 
The Methods section must include a statement that informed consent was obtained from patients, parents or guardians 
when appropriate. It should also state that the human experimentation guidelines of the National Department of Health 
(http://www.doh.gov.za) or the South African Medical Research Council (MRC; 
http://www.sahealthinfo.org/ethics/index.htm) and/or those of the authors� institution(s) were followed in the conduct 
of clinical research or that animal experimentation guidelines (see MRC website above) were followed in animal 
studies. Non-South African studies should contain similar declarations relating to local guidelines where appropriate. 
The trial number of the approving body (bodies) should be stated when relevant. 
Tables and Figures 
Refer to the manuscript categories for prescribed number of tables and figures. Written permission from the author or 
copyright holder must be submitted for reprint of previously published figures or tables. Figures should be saved as high 
resolution (300 dpi) jpeg files. Tables should be constructed in MS Word. Graphs can be copied from MS Excel and 
pasted in the document. For large, intricate graphs, the coordinates and graphs must be provided as separate MS Excel 
files and uploaded as supplementary files. 
Tables and figures can be in the text at the relevant place. Large tables (landscape A4) and photographic images are best 











Figures and photographs should be of high quality with symbols, letters or numbers clear enough and large enough to 
remain legible after reduction. Remove all markings, such as patient identification, from radiographs before 
photographing. Each figure must have a separate self-explanatory legend. 
Footnotes 
Examples of information that can be submitted as a footnote to the manuscript include: 
Statement that authors either have or have not a potential conflict of interest.  
Statement naming sources of financial support. 
Information of previous presentation of part or all of the data. 
Current affiliations and addresses for authors whose affiliations have changed since completion of the study. 
Acknowledgements of financial support received or substantial contributions to the research or preparation of 
the manuscript made by persons other than the authors. 
References 
References should be cited in numerical order in the text, in superscript format (Format> Font> Click superscript) 
AFTER the full stops. (Not in brackets or as footnotes.) 
References must be typed double-spaced and numbered consecutively in the order in which they are cited, not 
alphabetically. 
The style for references should follow the format set forth in the Uniform Requirements for Manuscripts Submitted to
Biomedical Journals (http://www.icmje.org) prepared by the International Committee of Medical Journal Editors.
Abbreviations for journal titles should follow Index Medicus format.
Authors are responsible for the accuracy of all references. Personal communications and unpublished data should only 
be referenced in the text. 
List all authors when there are six or fewer; when there are seven or more, list the first six, then "et al." When citing 
URLs to web documents, place in the reference list, and use the following format: Authors of document (if available). 


























3-Mixed germ cell 
MTMT 
Others 
* if IMT grade?
Stage of the disease: 
Ia IIa IIIa VI 
Ib IIb IIIb 











Tumour markers (initial value): 
bHCG LDH AFP CA125 other N/S 
HIV status: 
Yes    (if yes – enter below) No N/S 
CD4 
Sequences of treatment 
Surgery chemo radiotherapy 
S C R 






PALN removal or biopsy 
Cytoreduction 
Other 
2 nd look lap 
Chemotherapy given: 
Yes no 
  If yes type of chemo: 











Chemo no. cycles: 
Any major side effects? 
Radiotherapy given: 
Yes No 




Pelvis +Extended field 
Primary treatment course completed: 
Yes No *
If No: Reason (free text):………………………………………………
Relapse : 
Yes 
Locoreg Dist both 
No 
Date of relapse:………………………………………. 
Treatment of relapse: 











Response to primary therapy: 
CR PR NR PD NE 
Current status: 
Alive NAD Alive dis Lost Dead 
dis treat othe 
Date last seen/Died:………….. 
DFS:………………………..months OS:…………………………..months














Ethic committee approval 
"~_.· ...... H_.C _ • • _ .,,-><--,' ............ "_ .. -' 
-"'''--,.-
, .. .. ""'_ J ,,"_""L v_ ~1jI< 
,~ .. '" ".-..-
' P.\> 
"'----"'" T"'-_ =' "" .... . ..... _"'- «'''''' 
_"'~ " ._'IO"'r~ 
r. ~. ,,"_ ..... " . ... . .. , •••. ,~._ C,,_ .. , --. .. __ ... ,_"V' ,_, _ '" 
'T1"." ... ~_ •• '" _..., .... " ..... ..,. ,,'U, 
""",, , '." -.-,. ---. ," , - " ", " ,. .. . , . . _ .. _ ~ . " . .. '0 ~. _ ",." , _ t"f'~ " jt_ 
, ..... ", '0'" _'0 0' ......... ~,." ", ~, '" ... _ ... " .. ""' ..... , r., o • •• " "'_ 
- " .... , .. _ .. _ ..... _ .. ... ..• , .n.~ "" """' ... .. _" ... ~;. '" _W . . ... 














Clinical Directorate of Groote Schuur Hospital approval 
DEPARTMENT 
of HEALTH 
""""" ,, '''''''' ' ", 
, .. >hom .... , ~ ,'-'00 W" L 
<>'-'_ ..... 
r" <',<, ,,,,,,, 
'-i"' ,""h ' ,> , ,*,,, 
~ ,.c_ 
,..",x:, 
c."""" '" m • • " "" " 
"-",",,,.-, .. ,.-... ~ ~ ,. '"'~ , .. 
" " --~"-~-. ", ... ,~".,- . , ., .-
'UOO "OJlCl, ", ... ' " .. , .... , ,,"' .... ",,-,,=-, of Goo~ C .. , ~ .. ,~ 
""'" ,.,.., .. ""'"'" k ........ _. Copo , ._. ""'<w<C" " "_,""" • 
' .. 0 .... 0 ... ....,.-
" >0-" ,.,. ~oh -",., cor ~_ .• ',"" "~,'" pot. " ocr< 
t< ""to;,,' - "'''' ... ',",00 " 0;'" .;;' , ... """~, ~ 
" '" b "" _0 ,,""'., ~ ~ " . 0 ~ ,' , ~ ~ _, .0 . .. ..., _  ,.....- .. ·_~.H~ ........... ,~ .. .... o . ....... 
' .' .. W, H , d .'" ~''' '' ' ,., "" ,,,,;', ., . ,,,"" " '"' '"'' ' '''''~, 
"" "" "'",,'. , k.~_ . .-"c ,'~ -t." ,., "" d -,~ '"' , d of ' 0."-. ,,~ ., >r<.ok.,,· -".'.>~ 

















University of Cape Town (Dean circular approval) 
~~.~,~.,~=* 
"~"' ., ~~~~~"' 
00 .. ' ".,. " ... 
, ~,- .,,~ ~,-. - , ... , . - ,~. ~"-.. ,~ ... ,,.,-
." ••• "m 
_,e. ,o·,_ . " .. ·~_N_ .. ,.'~ •• ", .. ,. , •• ·, ___ " .. , ..... "' .. ".~,_~ .~~ ...... 
~~N' __ . .. ,_" .. ___ , ._, . ~., .... _ _ . , _ ,. _ _ "_ " ." " ~~ " _N 
~.,. _ . " • • • _ ... ~". __ WH ,~_ •• , 













.. Wolters Kluwer 
H".lIh 
GROOT'O< ~~~(J\JI\ H05 F ,n ... '. 
Wt Ll>CtI VAIf IIlJI< 
OBSE1\VATORI 
792~ C1\.Pr. 1(lIrtO 
S<Xrl'H "f1\ I CA 
~  WiUiorm & WilUl, 
3S1 W. c..,rlon 1 ..... ' 
O I!ti""""<MO~lWl 
.J:nvoic<> • ~M13~~ Oo Cu.to .. ~r ~ O Dn 'lej~ 3 1"96 
R .. : , unT, JRIIT. G:t" P~"H 
Spo<' l!~ t ; (>C(> 110m J.,M, 2006;25, 305 20.T91 
n'VOI!;" 1\II i) COIIDI T10ltS 
0 ,00 
410 518 4000 . tl 
www_lWW~."'" 
I'.,rllli ... sion h ",."ned fOY you~ r .. qu .. atr.d " "". n"" 3e ,,19" .. ,," dat-It ~hh 
ror ... nd ~.tgm \lit h pA_"t ( i f ~,,(>ll c .. bt,,) in til ...... <:1""..., "nvel<l(>e. 
1'1".,." "",Ul " " " <IVY (O~ yo,, ~ til.a . "II I I' r"",. ; uiu" 1" . ... b1<1ct to tllQ 
toll""'in~ COml1U O" .' 
l) A ~c &dl t, lin .. ~i11 b.. pHmiltl"Uy plAc<><l ,nd t"cl",\<>, lo r lx>ob t_:r,~ 
auth<>r( . ) , tith a t l>oo~, .... tL t<.>r, (,.·""yrignt hol<ln: . I'ElU Q( publl~~U"": 
f or )OUn\~ J ~ _ ~he ~ l\th"r{'I, title e f Ht1cl~ , t.it l ~ n f ) <>u ".."l, .,." lul"" 
nlltolX!1, 13~U~ n\lJlber at><! 1nclu~i,,~ p.>'-l('!~ . 
'1 'l'he ~ ... n o' .... rriillt~ tb~ t til ... ~u . .. l~l shall nut bu njJecl i n ;my .... ,,"U 
",Mch .... '1 be eond .... r ..... oJe r O!lHOr v to thq ti t a. eont ent . O~ a u t hor" of 
til~ .... t.ti.a l or to Ll.'lI. 
3 1 p.".l u ion i ~ ?r .. <>t. d [or " .... ~IO'" u$" ""lV a~ .peci H .<t in v"",r 
=aupn'~n<: • . ~.i<1ht ~ herein Q.Q not . pply to r"~U':d r"lIr,.,hw t l "n3, 
~<Ji tiQne, r.vi.ten ; , el: eth .. t eI"ri vILUve ,", orh. 
4) P~no l. M1on qrnnhd i~ non - u,,,l,,dve . and i, ... " HeI tllrC\ll/llout the ;"orld 
iI) t il.. Englhh hngn .. 'l ~ only. 
~ ) lJio"'ll ,~nnot supply the ... """ner .. Hh th .. <>r i l>i ,,~l Ilr twork e~ 
a · "lu" copy . • 
6 J The t""",o~tor '"11" .... " t o 3~"r .. .. ritt<'.n pe""' ''31on flO .. t~ ""t.llor ([o r 
boQ t .. udal <I<'o1y) . 
7) p~OI.haion i ~ .... lid it ~he bOt:r<>wcd ••• >tor 1.1 10 OrJ Qi nd to a T.I!I/ i"4>ril'lt 
l1.ippin.:o~(', · "'ave " Publi;nuu, II1111" M3 , l-1ilkins, Le a , !'~ biq~ r. TT u wa J., 
Iqah-~lloin, R~1'1d ~c1"nce, Litt l!l I3rO+ln a mt "","pa nt, "a rp~r • R,"" H~di" .. l 
A"",riCftn Journd ()f Nnr, i ,,\) C", ~ OO IJrb~n , r,('Jll,~"<a nu..l'q 
- f:n..-U "h t~ "gu"IJ") . 
8) 1'~)'<IOI.>t ca., be .... <J~ via C~ed1t cftrd I"""'x, VI SA, Due" .... ~nd K::) 
or by clloc~ . 
~J If you Opt no ... t o u~ .. u... ~' ·ed. l ""'1UCH'>d abOve, pluu ""t:Hy 
LWlf " ith, n ~O d..Y8 o[ ... he orlq., n . 1 Ln",olc~ dlI.t~. e'I C" Ga not .. .. Her 
9Q d.a ya, LII'W will nnl <};'I.n<>e i/or edJ t. ynur ""'l"e.t whioh d U ~"6u T l 
i n t o & ~ollectic" iHU". 
C,U d l~jJ O~tD' ___ __ _ 
Ruq .. "st<>r .0000pt~, llan, _ __ _ 
